Aurelie Wiedemann

Université Paris Est
Creteil, France

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 40 publications

Cross-Reactive Bundibugyo Antibody Responses after Receipt of Licensed Ebola Vaccines.

Cross-Reactive Bundibugyo Antibody Responses after Receipt of Licensed Ebola Vaccines.

Journal: The New England journal of medicine

Published: July 22, 2026

Five-year immunogenicity and safety follow-up of the PREVAC randomized Trial of Vaccines for Zaire Ebola Virus Disease.

Five-year immunogenicity and safety follow-up of the PREVAC randomized Trial of Vaccines for Zaire Ebola Virus Disease.

Journal: medRxiv : the preprint server for health sciences

Published: June 22, 2026

Cross-reactive Bundibugyo antibody responses after licensed Ebola vaccines.

Cross-reactive Bundibugyo antibody responses after licensed Ebola vaccines.

Journal: medRxiv : the preprint server for health sciences

Published: June 05, 2026

SARS-CoV-2 mRNA XBB1.5 vaccine immunogenicity in kidney transplant recipients.

SARS-CoV-2 mRNA XBB1.5 vaccine immunogenicity in kidney transplant recipients.

Journal: Virology journal

Published: February 06, 2026

CD40.HIVEnv, an antibody mediated vaccine, induces long-term and recall immunogenicity in non-HIV-1 infected volunteers.

CD40.HIVEnv, an antibody mediated vaccine, induces long-term and recall immunogenicity in non-HIV-1 infected volunteers.

Journal: Scientific reports

Published: January 06, 2026

Characterization and comparison of immunity against MPXV for individuals infected with MPXV or vaccinated with modified vaccinia Ankara vaccines.

Characterization and comparison of immunity against MPXV for individuals infected with MPXV or vaccinated with modified vaccinia Ankara vaccines.

Journal: Journal of immunology (Baltimore, Md. : 1950)

Published: September 18, 2024

Safety and immunogenicity of CD40.HIVRI.Env, a dendritic cell-based HIV vaccine, in healthy HIV-uninfected adults: a first-in-human randomized, placebo-controlled, dose-escalation study (ANRS VRI06).

Safety and immunogenicity of CD40.HIVRI.Env, a dendritic cell-based HIV vaccine, in healthy HIV-uninfected adults: a first-in-human randomized, placebo-controlled, dose-escalation study (ANRS VRI06).

Journal: EClinicalMedicine

Published: July 08, 2024

Long-term cellular immunity of vaccines for Zaire Ebola Virus Diseases.

Long-term cellular immunity of vaccines for Zaire Ebola Virus Diseases.

Journal: Nature communications

Published: April 16, 2024

Innate and Cellular Immune Response to the Ebola Vaccine Ad26.ZEBOV, MVA-BN-Filo: An Ancillary Study of the EBL2001 Phase 2 Trial.

Innate and Cellular Immune Response to the Ebola Vaccine Ad26.ZEBOV, MVA-BN-Filo: An Ancillary Study of the EBL2001 Phase 2 Trial.

Journal: The Journal of infectious diseases

Published: March 15, 2024

Subunit protein CD40.SARS.CoV2 vaccine induces SARS-CoV-2-specific stem cell-like memory CD8+ T cells.

Subunit protein CD40.SARS.CoV2 vaccine induces SARS-CoV-2-specific stem cell-like memory CD8+ T cells.

Journal: EBioMedicine

Published: September 10, 2023

Correction to: Neutrophil Activation and Immune Thrombosis Profiles Persist in Convalescent COVID‑19.

Correction to: Neutrophil Activation and Immune Thrombosis Profiles Persist in Convalescent COVID‑19.

Journal: Journal of clinical immunology

Published: March 29, 2023

Complement-dependent mpox-virus-neutralizing antibodies in infected and vaccinated individuals.

Complement-dependent mpox-virus-neutralizing antibodies in infected and vaccinated individuals.

Journal: Cell host & microbe

Published: March 21, 2023

Showing 1-12 of 40

Last Updated: 09/26/2026